drugset
drugset / Trial / NCT06091748

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

NCT06091748 ↗

Phase 3 Completed 69 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelDiagnostic

Summary

This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.

Timeline

Start
2024-02-22
Primary completion
2025-11-27
Completion
2025-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATOC Peptide — —

Indications

digestive system neuroendocrine neoplasm